Gary Condran

Manager, Quality Risk Management Division, Bureau of Pharmaceutical Sciences, Pharmaceutical Drugs Directorate (PDD)
Health Canada

After obtaining his Science degree majoring in Chemistry from Acadia University in Nova Scotia, Canada, Gary Condran was employed for several years in the Regulatory Affairs Departments of two multi-national generic pharmaceutical companies (Novopharm Ltd. and Genpharm Inc, at the time) in the Toronto area. Gary joined Health Canada in 1995 and has since held several positions across the Department, including Senior Evaluator, Senior Scientific Advisor, and most recently Manager of the Quality Risk Management Division within the Bureau of Pharmaceutical Sciences.

He has had the great opportunity to participate as Health Canada’s representative on ICH’s Q1 Stability and Q3A/Q3B Impurity working groups and ICH’s Quality Discussion Group and was the ICH Regulatory Chair for the Q11 Q&A document on API Starting Materials. Gary is also involved in several international, bi-lateral and multi-lateral regulatory collaborative activities and in Health Canada’s task group managing and responding to the risk issues associated with N-Nitrosamine impurities in pharmaceuticals.

Skip to content